TY - JOUR
T1 - Impact of cachexia on outcomes in aggressive lymphomas
AU - Karmali, Reem
AU - Alrifai, Taha
AU - Fughhi, Ibtihaj A.M.
AU - Ng, Ronald
AU - Chukkapalli, Vineela
AU - Shah, Palmi
AU - Basu, Sanjib
AU - Nathan, Sunita
AU - Szymanski-Grant, Kelly
AU - Gordon, Leo I.
AU - Venugopal, Parameswaran
AU - Penedo, Frank J.
AU - Borgia, Jeffrey A.
N1 - Publisher Copyright:
© 2017, Springer-Verlag Berlin Heidelberg.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Cancer cachexia is defined as a state of involuntary weight loss, attributed to altered body composition with muscle mass loss and/or loss of adiposity. Identifying the association between cancer cachexia and outcomes may pave the way for novel agents that target the cancer cachexia process. Clinical parameters for measurement of cancer cachexia are needed. We conducted a single-institution retrospective analysis that included 86 NHL patients with the aim of identifying an association between cancer cachexia and outcomes in aggressive lymphomas using the cachexia index (CXI) suggested by Jafri et al. (Clin Med Insights Oncol 9:87–93, 15). Impact of cachexia factors on progression-free survival (PFS) and overall survival (OS) were assessed using log-rank test and Cox proportional hazards regression. Patients were dichotomized around the median CXI into “non-cachectic” (CXI ≥49.8, n = 41) and “cachectic” (CXI <49.8, n = 40) groups. Cachectic patients had significantly worse PFS (HR 2.18, p = 0.044) and OS (HR = 4.05, p = 0.004) than non-cachectic patients. Cachexia as defined by the CXI is prognostic in aggressive lymphomas and implies that novel therapeutic strategies directed at reversing cachexia may improve survival in this population.
AB - Cancer cachexia is defined as a state of involuntary weight loss, attributed to altered body composition with muscle mass loss and/or loss of adiposity. Identifying the association between cancer cachexia and outcomes may pave the way for novel agents that target the cancer cachexia process. Clinical parameters for measurement of cancer cachexia are needed. We conducted a single-institution retrospective analysis that included 86 NHL patients with the aim of identifying an association between cancer cachexia and outcomes in aggressive lymphomas using the cachexia index (CXI) suggested by Jafri et al. (Clin Med Insights Oncol 9:87–93, 15). Impact of cachexia factors on progression-free survival (PFS) and overall survival (OS) were assessed using log-rank test and Cox proportional hazards regression. Patients were dichotomized around the median CXI into “non-cachectic” (CXI ≥49.8, n = 41) and “cachectic” (CXI <49.8, n = 40) groups. Cachectic patients had significantly worse PFS (HR 2.18, p = 0.044) and OS (HR = 4.05, p = 0.004) than non-cachectic patients. Cachexia as defined by the CXI is prognostic in aggressive lymphomas and implies that novel therapeutic strategies directed at reversing cachexia may improve survival in this population.
KW - Cachexia
KW - DLBCL
KW - Non-Hodgkin lymphomas
KW - Outcomes
KW - Pathophysiology
KW - Prognostic factors
UR - http://www.scopus.com/inward/record.url?scp=85017522750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017522750&partnerID=8YFLogxK
U2 - 10.1007/s00277-017-2958-1
DO - 10.1007/s00277-017-2958-1
M3 - Article
C2 - 28417157
AN - SCOPUS:85017522750
SN - 0939-5555
VL - 96
SP - 951
EP - 956
JO - Annals of Hematology
JF - Annals of Hematology
IS - 6
ER -